In addition, overtreatment of hypoglycemia can lead to rebound hyperglycemia and contribute to increased glycemic variability and diminished time in range.7 However, clinical guidelines for CHO treatment of hypoglycemia8,9 have not been revised to reflect the impact of reduced insulin delivered by advanced insulin delivery systems. This evidence concerns the gene INS and Hyperglycemia.